Latest research on Fluticasone

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Fluticasone indications

Also in a retrospective pooled analysis of 5 RCTs comparing Zafirlukast to Fluticasone as monotherapy, the effects of Zafirlukast appeared to be lost in older adults (aged ≥50 years) [72]. [source, 2016]
Fluticasone propionate (FP), either alone or in association with other bronchodilators, is one of the most commonly prescribed ICSs because it is considered effective and well tolerated [1]. [source, 2016]
The most effective agent was Fluticasone according to the SUCRA curves (96%), which was followed by indacaterol/glycopyrronium (80%), and mometasone/formoterol (80%). [source, 2015]
For this network meta-analysis, Fluticasone, indacaterol/glycopyrronium and mometasone/formoterol were the most effective agents at reducing the risk of moderate-to-severe COPD exacerbations. [source, 2015]
In murine models, nitro-FAs displayed antidiabetic actions, reduced vascular inflammation, attenuated hypoxia-induced pulmonary hypertension, and reduced the severity of allergic airways disease being more effective than Fluticasone propionate in contrasting neutrophilic inflammation [87, 96, 125, 126]. [source, 2015]
Several studies could not reveal systemic side effects [1356], [1357], [1358], even in cases of significantly higher Cortisone doses (3 mg Fluticasone 2x per day for 6 weeks, [1359]). [source, 2015]
In COPD, the current indication for the use of different fixed combinations of ICS and long-acting β2-agonist is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the accepted FEV1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (Fluticasone propionate–salmeterol) and to <70% predicted (Fluticasone furoate–vilanterol). [source, 2015]
Dymista (MP29-02*) is a novel intranasal formulation of Azelastine Hydrochloride (AZE) and Fluticasone propionate (FP) in an advanced delivery system with a well-documented effect on allergic rhinitis. [source, 2015]
The bronchodilating effects of formoterol and Salmeterol are further sustained when administered concomitantly with Budesonide and Fluticasone, respectively. [source, 2015]
This tested the effects of high-dose Fluticasone, 1 mg twice daily, (equivalent to 2 mg twice daily of Beclometasone [26] or 8.5 mg of oral Prednisolone [27]) for 2 weeks in non-asthmatic adults presenting to Dutch primary care with a cough (LRTI) lasting more than 2 weeks. [source, 2015]